| Filed On | Filing |
|---|---|
| 01 Oct 2026 | 144 |
| 25 Sep 2026 |
Form 4: Woods Keith, Chief Operating Officer
Gave 48,034 shares as a gift |
| 23 Sep 2026 |
Form 4: Hallal David, Director
Gave 36,652 shares as a gift |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
On September 14, 2026, Scholar Rock Holding Corporation (the “Company”) hosted a live audio webcast (the “Investor Call”) announcing that the U.S. Food and Drug Administration (“FDA”) has approved ISEMBYLD™ (apitegromab-mstn) for the tre... |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | 424B5 |
| 06 Aug 2026 | 8-K: Other Events |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 06 Jul 2026 |
Form 4: Flier Jeffrey S., Director
Sold 3,053 shares ($164K) |
| 06 Jul 2026 |
Form 4: Burow Kristina, Director
Sold 3,053 shares ($164K) |
| 06 Jul 2026 |
Form 4: Reed Joshua, Director
Sold 3,053 shares ($164K) |
| 06 Jul 2026 |
Form 4: Peng Katie, Director
Sold 5,446 shares ($293K) |
| 06 Jul 2026 | 144 |
| 06 Jul 2026 |
Form 4: Gilman Michael, Director
Sold 2,544 shares ($137K) |
| 01 Jul 2026 | 144 |
| 01 Jul 2026 | 144 |
| 01 Jul 2026 | 144 |
Loading...
